CILcare will be attending the 17th Annual Discovery on Target on September 16-19, 2019 in Boston. Meet Sylvie PUCHEU, Ph.D, CSO, with her presentation on Preclinical approaches to develop treatment for tinnitus on 17th of September at 11:55 AM (Lead Generation Strategies).
Tinnitus is the perception of a phantom sound without a corresponding external sound source. The physiopathology of tinnitus is caused by abnormalities in the inner ear and dysfunctions of the central nervous system. CILcare proposes two tinnitus models: salicylate-induced tinnitus and noise-induced tinnitus, which allow to test reversible and chronic tinnitus.
Read CILcare’s publications and scientific journal articles related to hearing disorders.
The 17th Annual Discovery on Target (DOT), the industry’s preeminent event on novel drug targets and technologies, will convene over 1,300 drug discovery professionals in Boston, MA, on September 16-19, 2019. This event highlights advances in current and emerging “hot” targets and technologies, as well as target validation strategies for the discovery and development of novel therapeutic agents, ranging from biologics to small molecules. Delegates can customize their experience at the event by choosing from 14 conference programs, plus focused training seminars, comprehensive short courses, moderated roundtables and networking functions to meet their own research needs and those of their organizations.
Additions for 2019 include new programming dedicated to PROTACs and their applications, drugs and targets in fibrosis, novel immune-oncology targets, RNA as an emerging target for small molecule drugs, along with expanded coverage of protein engineering and novel biotherapeutics.